Cardiac preconditioning by specific ligands of Toll-like receptors: is it wither or whither?
Chatterjee
Prabal K
PK
D000818:Animals; D002460:Cell Line; D054360:Chemokine CXCL1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D018925:Chemokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D019157:Ischemic Preconditioning, Myocardial; D007962:Leukocytes / Q000276:immunology*; D055666:Lipopeptides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009203:Myocardial Infarction / Q000276:immunology; D015428:Myocardial Reperfusion Injury / Q000235:genetics* / Q000276:immunology*; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051195:Toll-Like Receptor 2 / Q000819:agonists* / Q000235:genetics*; D020107:Troponin T / Q000378:metabolism
D054360:Chemokine CXCL1; D018925:Chemokines; C475895:Cxcl1 protein, mouse; D055666:Lipopeptides; C508075:Pam(3)CSK(4) peptide; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D020107:Troponin T